Related Experiment Video
Updated: Mar 15, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
Published on: October 9, 2014
Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic
Andrea Pellagatti1, Jacqueline Boultwood1
1Bloodwise Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford; NIHR Biomedical Research Centre, Oxford, UK.
Abstract:
Splicing factor gene mutations are the most frequent mutations found in patients with the myeloid malignancy myelodysplastic syndrome (MDS), suggesting that spliceosomal dysfunction plays a major role in disease pathogenesis. The aberrantly spliced target genes and deregulated cellular pathways associated with the commonly mutated splicing factor genes in MDS (SF3B1, SRSF2 and U2AF1) are being identified, illuminating the molecular mechanisms underlying MDS. Emerging data from mouse modeling studies indicate that the presence of splicing factor gene mutations can lead to bone marrow hematopoietic stem/myeloid progenitor cell expansion, impaired hematopoiesis and dysplastic differentiation that are hallmarks of MDS. Importantly, recent evidence suggests that spliceosome inhibitors and splicing modulators may have therapeutic value in the treatment of splicing factor mutant myeloid malignancies.
Insights
Mutations in splicing factor genes are common in myelodysplastic syndromes (MDS), a myeloid malignancy. Targeting spliceosome dysfunction shows promise for treating these splicing factor mutant myeloid malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- Splicing factor gene mutations are prevalent in myelodysplastic syndromes (MDS).
- Spliceosomal dysfunction is implicated in MDS pathogenesis.
- Commonly mutated genes include SF3B1, SRSF2, and U2AF1.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying MDS.
- To identify aberrant target genes and deregulated pathways in MDS.
- To explore potential therapeutic strategies for MDS.
Main Methods:
- Identification of aberrantly spliced target genes.
- Analysis of deregulated cellular pathways.
- Utilizing mouse modeling studies.
Main Results:
- Splicing factor gene mutations lead to hematopoietic stem/myeloid progenitor cell expansion.
- Impaired hematopoiesis and dysplastic differentiation are observed.
- Mouse models recapitulate key features of MDS.
Conclusions:
- Spliceosome dysfunction is a key driver of MDS.
- Understanding molecular mechanisms is crucial for MDS treatment.
- Spliceosome inhibitors and splicing modulators may offer therapeutic benefits for MDS.
Related Concept Videos
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
RNA Splicing
RNA Splicing
Pre-mRNA Processing: RNA Splicing
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...

